AN2 Therapeutics Pauses Trial: Efficacy Concerns Rise
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
- Latest
- Trending
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
Discover the winners and losers in the stock market, including tech giants Microsoft and NVIDIA, as well as underperformers Intel ...
Discover the enduring strength of mega-cap stocks like Mastercard, Walmart, and Merck amidst global uncertainties. These companies have consistently provided ...
GSK and Elegen partner to develop new vaccines and medicines, harnessing Elegen's DNA manufacturing technology. Collaboration aims to expand genetic ...
Ault Alliance, Inc. declares monthly cash dividend for preferred stock, showcasing commitment to rewarding shareholders and financial stability.
Teva completes enrollment for Phase 3 trial of mdc-TJK, a potential treatment for schizophrenia. Results expected in 2024. #schizophrenia #clinicaltrials
Johnson & Johnson's acquisition of Ambrx showcases the power of biotech M&A, rewarding investors with staggering returns and highlighting the ...
GSK's acquisition of Aiolos Bio expands respiratory treatment options, introducing AIO-001, a promising new treatment for asthma patients.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.